SMAD4 Deletion

CI-VAR-00000632Explore in graph →CIViC 646

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
SMAD4 Deletion	Fluorouracil	Predictive	B	Supports Resistance	3	accepted	EID1644 A retrospective study with 202 colorectal cancer patients found that SMAD4 deletion was associated with worse outcomes during 5-fluorouracil treatment. The hazard ratio for disease-free survival was 2… (full text at CIViC) PMID 12237773 · Boulay et al., 2002 · Open in CIViC	civic
Malignant Pancreatic Neoplasm1
KRAS G12D AND KRAS G12R AND CDKN2A Loss AND CDKN2B Loss AND SMAD4 Deletion AND TP53 R267W	Bevacizumab + Palbociclib + TrametinibCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID11711

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.